GlassScriptPhysician profile
Matthew J Cunningham
NPI 1114988904
$6,214.18
in general payments reported to CMS, 2019-2025
35 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $207 · 2021: $18.81 · 2022: $70.44 · 2023: $851 · 2024: $1,891 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,384 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.62 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.46 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $914.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $575.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $417.26 | 2019-2025 | Veozah |
| Amgen INC. | $343.91 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $336.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $289.56 | 2019-2025 | |
| Abbott Laboratories | $287.78 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $255.48 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.96 | 2019-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $184.29 | 2019-2024 | Belsomra, Verquvo, Capvaxive |
| Dexcom, INC. | $171.90 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $122.08 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $113.19 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $100.24 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $91.16 | 2025 | |
| Allergan, INC. | $74.16 | 2019 | |
| Verona Pharma, INC. | $74.11 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $66.85 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $66.25 | 2023-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $64.40 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.83 | 2024-2025 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $58.45 | 2019 | |
| Sunovion Pharmaceuticals INC. | $48.88 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.37 | 2025 | Caplyta |
| Lundbeck LLC | $29.82 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.53 | 2019 | |
| Amarin Pharma, INC. | $20.71 | 2020 | |
| Tactile Systems Technology INC | $19.48 | 2019 | |
| Radius Health, INC. | $17.76 | 2019 | |
| Mannkind Corporation | $16.50 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2024 | Zoryve |
| Amneal Pharmaceuticals LLC | $13.42 | 2023 | Unithroid |
| Alkermes, INC. | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.